From Research to Practice Examples from European projects

Transcription

1 From Research to Practice Examples from European projects Eberhard Schatz Project Coordinator

2 > European network since 2004 > Access to health and social services for marginalised groups > Financed by EC, DG Sante > More than 180 partners in all European countries Targetgroups and members: service provider researcher Peers and community members policy and decision makers

3 General objectives Facilitate exchange of information, experience and skills between health and social service providers, policy makers, researchers and community members Strengthen capacities of health and social service providers, policy makers, researchers and community members Contribute to evidence-based policy making in the field of BBID

4

5

6 From Research to Practice EU 28 survey and inventory RAR identify and describe harmful patterns Implementation targeted pilot interventions Training multiplier trainings based on results Toolbox build best practice guidance, resource centre

7 Hep C Initiative concept and results DPIP 2013 Eberhard Schatz

8 Partners Universities and Institutes NGO's and national networks Centre for Interdisciplinary Addiction Research of the Hamburg A-ClinicUniversity Foundation, (CIAR), Finland Germany European Networks Charles Action University Plus, Albania in Prague, First Faculty of Medicine, Department AIDES, France of Addictology (CUNI), Czech Republic Aids Copenhagen AIDS Hilfe Frankfurt Foundation e.v., Germany HIV Programme East West (CHIP), (AFEW), University The of Netherlands Association for Risk Reduction in Drug (ARUD), Switzerland Copenhagen Carusel Doctors Association, (UCPH), of the Romania World, Denmark France Institute Fixpunkt Eurasian of Public - VereinHarm Health, für suchtbegleitende Reduction University Network of Hilfen Porto e.v., (EHRN), (ISPUP), Germany Lithuania Portugal German Aids Organisation (DAH), Germany European Aids Treatment Group (EATG), Belgium Grupo Português de Activistas sobre Tratamentos de VIH/SIDA (GAT), National Portugal European Antidrugs Association Agency (NAA), for the Romania Study of the Liver (EASL), National Health Institute Service Executive for Health (HSE) andaddiction Welfare Services, (THL), Finland Ireland European Liver Patient Association (ELPA), Belgium Isle of Arran, Italy Public Health Agency of Catalonia, Government of Catalonia Piaget Harm Agency Reduction for Development International (APDES), (HRI), Portugal United Kingdom (ASPC), Scottish Spain International Drug Forum Doctors (SDF), Scotland for Healthy Drug Policies (IDHDP), University Swedish United Medical Drug Kingdom User Centre Union Ljubljana, (SDUU), Sweden Clinic for Infectious Diseases Trimbosand Institute, Febrile Network Illnesses, Infectieziekten Slovenia& Harm Reduction, the Netherlands International Network of People who Use Drugs (INPUD), University United of Applied Kingdom Sciences Frankfurt (FH FEM), Germany Eberhard Schatz

9 Concept Research Policy Training & Skill building

10 Why? Barriers to testing and treatment: - Health systemic/political level - Service provider level - Community and patient level

11 How? Research: Hepatitis C testing and treatment barriers among active drug users in 4 European cities

12 Result High uptake of HCV antibody testing among clients of lowthreshold services Main motive is that drug users want to know their status Infections with HCV are highly prevalent (77.5%) Treatment uptake is low with 33 drug users out of 179 who were anti HCV positive Main barriers to treatment: Staff did not recommend or offer HCV treatment Drug users fear side effects of medication Ressources to increase treatment uptake Good information on HCV and treatment drug + health services and physicians have a key role Additional support provided to patients by local drug service Revision of national/ regional guidelines /recommendations for HCV treatment

13 How? Capacity Buildding Peer Training Manual 6 modules Module 1: Understanding Module 2: HCV prevention Module 3: HCV testing and diagnosis Module 4: HCV treatment Module 5: Living with HCV Module 6: HCV advocacy and action planning

14 What happened after Porto? Our The I have user drug lobbied union users for was organsiation a special togetherepresentative JES with and Dublin Aids Deutsche for Alliance HCV coinfection Community Hilfe in have the board Response become of the increasingly the Dutch co-organiser association involvedof of in a people HCV. public and AIDS campaign We living are with partners and HIV. mass And in developing I media have become events the National to a liason raise awareness HCV at my local on Strategy, hospital hepatitis for we people C. have developing with co-infection. more active testing advicves and campaigns Joost to prevent Brantas, Emily viralthe infecions Reeper, Netherlands Ireland through quiting with injecting. Dirk Schaeffer, Germany

15 What happened after Porto? We have started with a range of activites: Together The peer with group the local in Helsinki harm reduction have service In developed UK harm we organised reduction a health a education services HCV video information including ourhcv community meeting services for members the are local under on community pressure hepatitis of C. re-tendering, Antwerp. Experts, budget cuts profesionals andwe payment are planning and by results experts a 3-year against liketraining me rehab and a users andprogramme recovery. panel gave I on wrote introductions educating to the Lancet health and and discussed BMJ professionals to address the challenges my on HCV. concern. with HCV. Over Steve On a Freer, various hundred England occasions users andwith other people who pharmaceuticals are interested attended we talkedthe on the seminar. consumer perspective. Tony And van personally Montfoort, I mbelgium starting with my personal treatment as well Sari Haikarainen, Finland

16 What happened after Porto? Together with the Greek Association of Patients with a Liver Disease We Together (Prometheus) have with celebrated we the organised other local World a drug publid Hepatitis services awareness Day 28 campaign th July, with witha a giant and free -in mobile Turin, entrance yellow JPK-roundtable letter we urged C. We that and offered the a presentation Italian ionfromation regarding and a rapid HCV test for thise who prevalences Harm wanted reduction to. The in a complimentary Network cohort of start adults advocating Facebook-page and a cohort where of adolescents people could upload from for their a personal Porto national City. strategy pictures One of plan also the on people was HCV a great speaking succes. at the The roundtable action started in Athens was including and traveled the local a strong to community other emphasis cities representative later on PWID. on. The who action was has part been of the documented on you advocacy Andrea tube: Fallerini, training. Infoshock He presented on the perception on HCV of people Hepatitis using C awareness drugs. campaign in Greece Ana Efi Kokini, Martins, Greece University of Porto, Public Health Institute (ISPUP) Eberhard Schatz

17 How? Capacity building: resource centre: > 250 entries > 19 categories

18 Result BMC reader

19 BioMed Central (BMC) open-access, peer-reviewed journal entitled Hepatology, Medicine and Policy: Scope: Hepatology, Medicine and Policy considers articles on liver disorders, including viral and non-viral hepatitis, with a focus on policy at all levels from clinical to health services research and public health.

20 How? Policy: overall advocacy goal is to Influence HCV policies and advocate for the development and implementation of evidence-based HCV strategies at the European and National levels. increase knowledge about HCV European and national policy guidelines rase awareness on the gap between the needs and the political responses for HCV in Europe increase the sustainable involvement, strengthening and participation of Civil Society on HCV policies decision making process Eberhard Schatz

21 Result Manifesto Scale up evidence based harm reduction services Access to HCV testing, treatment and care services Access to affordable HCV treatments Decriminalisation of people who use drugs Meaningful involvement of high risk communities Improved HCV and health Literacy Effective targeted HCV strategies and action plans

22 What s next? Develop the initiative to a sustainable platform Research Policy Training & Skill building

23 What s next? New project in the EC DG Sante health programme??? - 21 partner + 20 collaborating partner: Universities, Health Institutes, Community Organisations, NGO s, Networks, policy maker

24 From Research to Practice

25 Conclusion Research is indispensable for good practice implementations and policy - Research outcomes need to be better connected to practice and policy - Researcher need to listen to the needs of community and field workers - Community need to be involved in designing and implementing research - Community and HR organisations need to be equal partners - We know a lot, the political will is missing We need more focus on evidence to action

26 Please find out more at Thank you.